In last trading session, Acorda Therapeutics, Inc. (NASDAQ:ACOR) saw 2,796,421 shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $0.72 trading at -$0.06 or -8.04% at ring of the bell on the day assigns it a market valuation of $34.43 Million. That closing price of ACOR’s stock is at a discount of -286.11% from its 52-week high price of $2.78 and is indicating a premium of 41.67% from its 52-week low price of $0.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.62 Million shares which gives us an average trading volume of 5.87 Million if we extend that period to 3-months.
For Acorda Therapeutics, Inc. (ACOR), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.7. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.52 in the current quarter.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) trade information
In the face of being in the red today for losing -8.04%, in the last five days ACOR remained trading in the green while hitting it’s week-highest on Friday, Nov 13 when the stock touched $0.8423 price level, adding 14.77% to its value on the day. Acorda Therapeutics, Inc.’s shares saw a change of -64.81% in year-to-date performance and have moved -9.78% in past 5-day. Acorda Therapeutics, Inc. (NASDAQ:ACOR) showed a performance of 4.04% in past 30-days. Number of shares sold short was 7.24 Million shares which calculate 1.23 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $2.33 to the stock, which implies a rise of 223.61% to its current value. Analysts have been projecting $1 as a low price target for the stock while placing it at a high target of $5. It follows that stock’s current price would jump +594.44% in reaching the projected high whereas dropping to the targeted low would mean a loss of 38.89% for stock’s current value.
Acorda Therapeutics, Inc. (ACOR) estimates and forecasts
Statistics highlight that Acorda Therapeutics, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -4.99% of value to its shares in past 6 months, showing an annual growth rate of 0% while that of industry is 14.4. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -246.7% in the current quarter and calculating -2% decline in the next quarter. This year revenue growth is estimated to drop -26.9% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $25.86 Million for the same. And 3 analysts are in estimates of company making revenue of $24.83 Million in the next quarter that will end in March 01, 2021. Company posted $50.5 Million and $28.1 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to drop by -48.8% while estimating it to be -11.6% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 16.45% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 6.4% while estimates for its earnings growth in next 5 years are of 29%
Acorda Therapeutics, Inc. (NASDAQ:ACOR)’s Major holders
Insiders are in possession of 1.69% of company’s total shares while institution are holding 51.15% percent of that, with stock having share float percentage of 52.03%. Investors also watch the number of corporate investors in a company very closely, which is 87 institutions for Acorda Therapeutics, Inc. that are currently holding shares of the company. Renaissance Technologies, LLC is the top institutional holder at ACOR for having 3.84 Million shares of worth $1.98 Million. And as of September 29, 2020, it was holding 8% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 2.86 Million shares on September 29, 2020. The number of shares represents firm’s hold over 5.97% of outstanding shares, having a total worth of $1.47 Million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 1366942 shares of worth $1Million or 2.85% of the total outstanding shares. The later fund manager was in possession of 775.33 Thousand shares on July 30, 2020, making its stake of worth around $487.53 Thousand in the company or a holder of 1.62% of company’s stock.